B7-H3 hypoimmune CAR-T cells

B7-H3 hypoimmune CAR-T cells are an allogeneic, "off-the-shelf" chimeric antigen receptor (CAR) T-cell therapy designed to treat solid tumors, with a primary focus on intrahepatic cholangiocarcinoma (ICC). These cells are engineered using a proprietary hypoimmune (HIP) platform that utilizes CRISPR-Cas9 to disrupt the B2M, CIITA, and TRAC genes. This triple knockout strategy eliminates the expression of HLA Class I, HLA Class II, and the endogenous T-cell receptor, thereby preventing both host-versus-graft rejection and graft-versus-host disease (GvHD). To further enhance persistence, the cells are engineered to overexpress CD47, which serves as a "don't eat me" signal to evade innate immune clearance by macrophages and NK cells. The CAR construct specifically targets B7-H3 (CD276), a cell surface glycoprotein that is highly expressed in various solid tumors but has limited expression in normal tissues, allowing for targeted tumor cell lysis.

Other names

HIP B7-H3 CAR-T cellsallogeneic HIP B7H3 CAR-T cellsB7-H3 HIP CAR-TB-7-H3 HIP CAR-TB 7-H3 HIP CAR-T